Challenging allograft use for aortic valve infective endocarditis: Is it the allograft or the surgeon? Syed T. Hussain, MD, Eugene H. Blackstone, MD,

Slides:

Advertisements

Similar presentations

Operative outcomes in mitral valve surgery: Combined effect of surgeon and hospital volume in a population-based analysis Arman Kilic, MD, Ashish S.

Advertisements

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Of mice and men and surgical transcatheter aortic valve insertion

Stapled excision of the left atrial appendage

Residual patient, anatomic, and surgical obstacles in treating active left-sided infective endocarditis Syed T. Hussain, MD, Nabin K. Shrestha, MD, Steven.

Challenging homografts as the holy grail for aortic valve endocarditis

Lars G. Svensson, MD, PhD, Eugene H. Blackstone, MD

A comprehensive review of the PARTNER trial

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

Endovascular versus open elephant trunk completion for extensive aortic disease Eric E. Roselli, MD, Sreekumar Subramanian, MD, Zhiyuan Sun, BS, Jahanzaib.

Surgical treatment of pseudoaneurysm of the thoracic aorta

Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Victor van Berkel, MD, PhD

Multilevel data analysis: What? Why? How?

Should lung transplantation be performed using donation after cardiac death? The United States experience David P. Mason, MD, Lucy Thuita, MS, Joan M.

Bicuspid aortic valve aortopathy: One size fits all?

Mechanical valves versus the Ross procedure for aortic valve replacement in children: Propensity-adjusted comparison of long-term outcomes Bahaaldin.

A. Marc Gillinov, MD, Eugene H. Blackstone, MD, Edward R

Capturing echocardiographic allograft valve function over time after allograft aortic valve or root replacement M. Mostafa Mokhles, PhD, MSc, Jeevanantham.

Bigger The Journal of Thoracic and Cardiovascular Surgery

Use of annulus washer after debridement: A new mitral valve replacement technique for patients with severe mitral annular calcification Syed Tarique.

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

The lord of the rings Antonio Miceli, MD, PhD

A. Marc Gillinov, MD, Patrick M. McCarthy, MD, Eugene H

The variability of the mitral valve anatomy and terminology

Support Your Specialty

Transcatheter aortic valve replacement in intermediate-risk patients

Innovation and science: The future of valve design

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

Michele Gallo, MD, Gino Gerosa, MD

Military surgeons just want to have fun

Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration.

Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,

Bahaaldin Alsoufi, MD, Cedric Manlhiot, BSc, Brian W

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

The Journal of Thoracic and Cardiovascular Surgery

Tirone E. David, MD, Gheorghe Gavra, MD, Christopher M

J. Jay Idrees, MD, Eric E. Roselli, MD, Amr Arafat, MD, Douglas R

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

The diabetes epidemic and its effect on cardiac surgery practice

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Replicating the success of mitral valve repair in the aortic valve

Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon

Commentary: Do the right thing! Ethical versus legal

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Hans-Joachim Schäfers, MD

Concomitant replacement of the ascending aorta is free—for some

In pregnancy, aortic tissue is the issue

Arvind K. Agnihotri, MD (by invitation), David C

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: Implications for transcatheter aortic valve replacement

Tissue valve, nitinol stent, or storage solution

A. Marc Gillinov, MD, Jon Sirak, MD, Eugene H

Permanent pacemaker insertion following transcatheter aortic valve replacement: Not infrequent, not benign, and becoming predictable Craig M. Jarrett,

Commentary: When a choice is not an echo

Aortic root surgery for young patients: The elephant in the room

Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement Todd M. Dewey,

Raja M. Flores, MD The Journal of Thoracic and Cardiovascular Surgery

Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD

“The more things change…”: The challenges ahead

Toward a more rational approach in treating type B aortic dissection

Racing to the Rubicon Michael J. Reardon, MD, Vinod H. Thourani, MD

Identifying risk factors: Challenges of separating signal from noise

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Journal changes and initiatives

Paul Philipp Heinisch, MD, Thierry Carrel, MD

Presentation transcript:

Challenging allograft use for aortic valve infective endocarditis: Is it the allograft or the surgeon? Syed T. Hussain, MD, Eugene H. Blackstone, MD, Gösta B. Pettersson, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 153, Issue 2, Pages 280-281 (February 2017) DOI: 10.1016/j.jtcvs.2016.09.005 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Hazard function for recurrent endocarditis in patients who underwent aortic valve replacement for infective endocarditis at an Australian center, stratified by mechanical prostheses and xenografts versus allografts. Early risk peaks within 6 weeks for the mechanical and xenograft group, compared with a low, constant risk in the allograft group. Dashed lines enclose 70% confidence limits. (Modified with permission from: McGiffin DC, Galbraith AJ, McLachlan GJ, Stower RE, Wong ML, Stafford EG, et al. Aortic valve infection. Risk factors for death and recurrent endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg. 1992;104:511-20. Copyright Elsevier 1992.) In contrast, patients who were treated for aortic prosthetic valve infective endocarditis with surgical debridement of infected tissue and aortic root replacement with a commercial cryopreserved aortic allograft at an American center had a late-peaking risk at approximately 9 months (inset). Dashed lines enclose 68% confidence limits. (Modified with permission from: Sabik JF, Lytle BW, Blackstone EH, Marullo AG, Pettersson GB, Cosgrove DM. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. Ann Thorac Surg. 2002;74:650-9; discussion 9. Copyright Elsevier 2002.) The Journal of Thoracic and Cardiovascular Surgery 2017 153, 280-281DOI: (10.1016/j.jtcvs.2016.09.005) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

The Journal of Thoracic and Cardiovascular Surgery 2017 153, 280-281DOI: (10.1016/j.jtcvs.2016.09.005) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions